Amycretin, developed by Novo Nordisk, is a single-molecule long-acting GLP-1 and amylin receptor agonist. Its mechanism of action achieves weight loss by simultaneously activating both receptors: • GLP-1 receptor activation: delays gastric emptying, promotes insulin secretion, and lowers blood sugar; • Activation of amylin receptors: It directly acts on the central nervous system, inhibits appetite and reduces energy intake. In July 2025, the molecular structure of Amycretin, a GLP-1 series product under Novo Nordisk, was officially disclosed.
Amycretin.png

The amycretin structure comprises a GLP-1 receptor agonist moiety (dark blue) and an amylin receptor agonist moiety (light blue) connected by a linker region (yellow). The amycretin peptide is acylated with a C18 diacid-based sidechain (white) at position K37 (when employing GLP-1 7-37 numbering). Aib, α-aminoisobutyric acid; Ala, alanine; Arg, arginine; Asp, aspartic acid; C, carbon; Gln, glutamine; GLP-1, glucagon-like peptide-1; Glu, glutamic acid; Gly, glycine; H, hydrogen; His, histidine; Ile, isoleucine; K, lysine; Leu, leucine; Lys, lysine; N, nitrogen; O, oxygen; OH, hydroxyl group; Phe, phenylalanine; Pro, proline; Ser, serine; Thr, threonine; Trp, tryptophan; Tyr, tyrosine; Val, valine.

Anyone need to enquire about the peptide raw materials, plz contact:
haoran.tse@gmail.com
+8618575536586

标签: none

评论已关闭